Five Facts about mental health
May 21, 2025Medical Communications, Medical Education, Research and Development European Commission, Pharmacy, Psychiatry, mental health, mental health condition
32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
Slingshot Therapeutics appoints Ed Savory as head of chemistry
May 21, 2025Research and Development Corporate, Pharmacy, Slingshot Therapeutics, appointment
Slingshot Therapeutics has announced the appointment of Ed Savory as head of chemistry. He will oversee the company’s chemistry strategy …
BioPhorum appoints Uwe Buecheler as non-executive director
May 21, 2025Medical Communications, Research and Development BioPhorum, Corporate, appointment, biopharma, medical communication
BioPhorum has announced the appointment of Uwe Buecheler as a non-executive director to its board. The company brings together leaders …
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
FDA approves Incyte’s new anal cancer treatment
May 20, 2025Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review
The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …
Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
Duck Creek Technologies appoints Tyler Jones as chief marketing officer
May 20, 2025Business Services, Pharmaceutical Consultancy Services Corporate, Duck Creek Technologies, appointment, chief marketing officer, property and casualty (P&C) insurance
Duck Creek Technologies has appointed Tyler Jones as its new chief marketing officer (CMO). He will lead the company’s global …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria
May 19, 2025Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)
A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …
Medable unveils oncology trial platform aimed at reducing logistical hurdles
May 16, 2025Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials
Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …
Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU
May 16, 2025Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia
Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
May 15, 2025Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
May 15, 2025Medical Communications, Sales and Marketing Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapy
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences …
Kaerus Bioscience secures FDA approval for rare genetic disorder treatment
May 15, 2025Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes
Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …
Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
May 14, 2025Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing
May 14, 2025Manufacturing and Production, Research and Development CGT production, Cell and Gene Therapy (CGT), Contraception, Pharmacy, Tozaro, advisory board
Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation of a Technical Advisory Board …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Donato Spota appointed as chief financial officer at Eleva
May 14, 2025Research and Development Eleva, Pharmacy, appointment, biopharma, chief financial officer (CFO)
German biopharma company, Eleva, has appointed Donato Spota as its new chief financial officer (CFO) and managing director to support …
Newron’s programme for treatment-resistant schizophrenia therapy approved
May 13, 2025Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
